Fore Biotherapeutics
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3675 Market St Ste 200, Philadelphia, Pe...Phone Number
(267) 641-7575Website
fore.bioRevenue
$10.6 MillionIndustry
About Fore Biotherapeutics
Fore Biotherapeutics is a virtual biotechnology company focused on precision oncology treatments for patients with hard-to-treat cancers, specifically targeting unaddressed mutations in established oncology pathways. Their lead program, Plixorafenib, is an investigational BRAF inhibitor designed to target a range of BRAF gene alterations in cancer cells. The company is committed to delivering high-impact therapies with speed and quality, currently conducting a phase 2 clinical trial for patients with advanced solid tumors harboring BRAF alterations. With a team of exceptional talent across the USA, Fore Biotherapeutics aims to fulfill the promise of targeted therapy through innovative research and development.Explore more
Fore Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Fore Biotherapeutics
Compare insights from companies similar to Fore Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Fore Biotherapeutics Tech Stack
A closer look at the technologies used by Fore Biotherapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Fore Biotherapeutics
Sign Up For FreeTo access detailed company insights
Fore Biotherapeutics is a virtual biotechnology company focused on precision oncology treatments for patients with hard-to-treat cancers, specifically targeting unaddressed mutations in established oncology pathways. Their lead program, Plixorafenib, is an investigational BRAF inhibitor designed to target a range of BRAF gene alterations in cancer... Read More
